![](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt70ff3b62858fc23c/6698fd23eb4f37051b35da09/Depositphotos_3918651_XL.jpg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale)
The contract development and manufacturing organization (CDMO) is expanding its Colorado, US, facility and constructing a greenfield site at an undisclosed site in Europe, enabling Corden to meet the growing demand for peptides.
The firm has set a sales target of €1 billion ($1.09 billion) by 2028 for its peptide platform. This platform is available in multiple facilities, including Colorado, its expanded facility in Frankfurt, Germany, and the under-construction site in Europe.
The peptide platform provides fully integrated peptide development and manufacturing services. Spanning from clinical stages to commercial supply, the platform produces peptide for active pharmaceutical ingredients (APIs) to drug products (DP), both for sterile injectables and oral solid dosage peptide delivery.